Management of osteoarticular fungal infections in the setting of immunodeficiency

References

• Bariteau JT, Waryasz GR, McDonnell M, et al. Fungal osteomyelitis and septic arthritis. J Am Acad Orthop Surg. 2014;22:390–401.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Walsh TJ, Sipsas NV. Epidemiology of fungal osteomyelitis. Curr Fungal Infect Rep. 2014;8:262–270.
   Google Scholar
• Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit Rev Microbiol. 2016;42:158–171.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(Suppl 3):47–75.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54:e666–e678.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419–4431.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl 1):48–66.
   PubMed Web of Science ®Google Scholar
• Taj-Aldeen SJ, Rammaert B, Gamaletsou M, et al. osteoarticular infections caused by non-Aspergillus filamentous fungi in adult and pediatric patients: a systematic review. Medicine (Baltimore). 2015;94:e2078.
   PubMed Web of Science ®Google Scholar
• Arias F, Mata-Essayag S, Landaeta ME, et al. Candida albicans osteomyelitis: case report and literature review. Int J Infect Dis. 2004;8:307–314.
   PubMed Web of Science ®Google Scholar
• Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints - a review from 2002 until today. Mycoses. 2014;57:323–335.
   PubMed Web of Science ®Google Scholar
• Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, et al. Bone and joint infections caused by mucormycetes: a challenging osteoarticular mycosis of the twenty-first century. Med Mycol. 2017;55:691–704.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Rammaert B, Bueno MA, et al. Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. Med Mycol. 2017;55:246–254.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Rammaert B, Bueno MA, et al. Candida arthritis: analysis of 112 pediatric and adult cases. Open Forum Infect Dis. 2016;3:ofv207.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Kontoyiannis DP, Sipsas NV, et al. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970–2011). Clin Infect Dis. 2012;55:1338–1351.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Rammaert B, Bueno MA, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect. 2014;68:478–493.
   PubMed Web of Science ®Google Scholar
• Rammaert B, Gamaletsou MN, Zeller V, et al. Dimorphic fungal osteoarticular infections. Eur J Clin Microbiol Infect Dis. 2014;33:2131–2140.
   PubMed Web of Science ®Google Scholar
• Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis. 2012;73:89–93.
   PubMed Web of Science ®Google Scholar
• Gabrielli E, Fothergill AW, Brescini L, et al. Osteomyelitis caused by Aspergillus species: a review of 310 reported cases. Clin Microbiol Infect. 2014;20:559–565.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 20(Suppl 3): 27–46. 2014. .
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–4752.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Walsh TJ, Zaoutis T, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Maraolo AE, Simeon V, et al. Changes in the relative prevalence of candidemia due to non-albicans Candida species in adult in-patients: a systematic review, meta-analysis, and meta-regression. Mycoses. 2020. DOI:10.1111/myc.13054
   Web of Science ®Google Scholar
• Kumashi PR, Safdar A, Chamilos G, et al. Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review. Clin Microbiol Infect. 2006;12:621–626.
   PubMed Web of Science ®Google Scholar
• Sim JP, Kho BC, Liu HS, et al. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J. 2005;11:120–123.
   PubMedGoogle Scholar
• Dotis J, Roilides E. Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses. 2011;54:e686–e696.
   PubMed Web of Science ®Google Scholar
• Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis. 2004;8:103–110.
   PubMed Web of Science ®Google Scholar
• Denes E, Boumediene A, Durox H, et al. Voriconazole concentrations in synovial fluid and bone tissues. J Antimicrob Chemother. 2007;59:818–819.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Wang K, et al. Fungal osteomyelitis after arthroscopic anterior cruciate ligament reconstruction: a case report with review of the literature. Knee. 2012;19:728–731.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Mete B, Ozaras R, et al. Aspergillus fumigatus infection as a delayed manifestation of prosthetic knee arthroplasty and a review of the literature. Scand J Infect Dis. 2011;43:573–578.
   PubMed Web of Science ®Google Scholar
• Durox H, Boumediene A, Genet C, et al. Disseminated aspergillosis after intra-articular corticosteroid infiltrations. Med Mal Infect. 2007;37:609–612.
   PubMed Web of Science ®Google Scholar
• Adler N, Seitz IA, Gottlieb LJ. Acute wound closure and reconstruction following head zygomycosis: presentation of two cases and review of literature. J Reconstr Microsurg. 2008;24:507–513.
   PubMed Web of Science ®Google Scholar
• Oo MM, Kutteh LA, Koc ON, et al. Mucormycosis of petrous bone in an allogeneic stem cell transplant recipient. Clin Infect Dis. 1998;27:1546–1547.
   PubMed Web of Science ®Google Scholar
• Echols RM, Selinger DS, Hallowell C, et al. Rhizopus osteomyelitis. A case report and review. Am J Med. 1979;66:141–145.
   PubMed Web of Science ®Google Scholar
• Moore PHJ, McKinney RG, Mettler FAJ. Radiographic and radionuclide findings in Rhizopus osteomyelitis. Radiology. 1978;127:665–666.
   PubMed Web of Science ®Google Scholar
• Huffnagle KE, Southern PMJ, Byrd LT, et al. Apophysomyces elegans as an agent of zygomycosis in a patient following trauma. J Med Vet Mycol. 1992;30:83–86.
   PubMedGoogle Scholar
• Weinberg WG, Wade BH, Cierny G, et al. Invasive infection due to Apophysomyces elegans in immunocompetent hosts. Clin Infect Dis. 1993;17:881–884.
   PubMed Web of Science ®Google Scholar
• Eaton ME, Padhye AA, Schwartz DA, et al. Osteomyelitis of the sternum caused by Apophysomyces elegans. J Clin Microbiol. 1994;32:2827–2828.
   PubMed Web of Science ®Google Scholar
• Meis JF, Kullberg BJ, Pruszczynski M, et al. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J Clin Microbiol. 1994;32:3078–3081.
   PubMed Web of Science ®Google Scholar
• Holtom PD, Obuch AB, Ahlmann ER, et al. Mucormycosis of the tibia: a case report and review of the literature. Clin Orthop Relat Res. 2000;381:222–228.
   Google Scholar
• Maliwan N, Reyes CV, Rippon JW. Osteomyelitis secondary to cutaneous mucormycosis. Report of a case and a review of the literature. Am J Dermatopathol. 1984;6:479–481.
   PubMed Web of Science ®Google Scholar
• Dinasarapu C, Auerbach J, Levi M, et al. Mucormycosis as a pathogen in polymicrobial necrotizing fasciitis. Infect Dis Clin Pract. 2010;18:417–418.
   Google Scholar
• Navanukroh O, Jitmuang A, Chayakulkeeree M, et al. Disseminated Cunninghamella bertholletiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review. Transpl Infect Dis. 2014;16:658–665.
   PubMed Web of Science ®Google Scholar
• Mostaza JM, Barbado FJ, Fernandez-Martin J, et al. Cutaneoarticular mucormycosis due to Cunninghamella bertholletiae in a patient with AIDS. Rev Infect Dis. 1989;11:316–318.
   PubMedGoogle Scholar
• Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, et al. Septic arthritis due to Absidia corymbifera in a patient with HIV-1 infection. Infection. 2008;36:279–281.
   PubMed Web of Science ®Google Scholar
• Pierce PF, Wood MB, Roberts GD, et al. Saksenaea vasiformis osteomyelitis. J Clin Microbiol. 1987;25:933–935.
   PubMed Web of Science ®Google Scholar
• Shaw CJ, Thomason AJ, Spencer JD. Fungal osteomyelitis of the foot. A report of an unusual case. J Bone Joint Surg Br. 1994;76:137–139.
   PubMedGoogle Scholar
• Muscolo DL, Carbo L, Aponte-Tinao LA, et al. Massive bone loss from fungal infection after anterior cruciate ligament arthroscopic reconstruction. Clin Orthop Relat Res. 2009;467:2420–2425.
   PubMed Web of Science ®Google Scholar
• Harrasser N, Gradl G. Mid-foot fractures of the chopart and lisfranc joint line. MMW Fortschr Med. 2014;156:54–55.
   PubMedGoogle Scholar
• Chen F, Lü G, Kang Y, et al. Mucormycosis spondylodiscitis after lumbar disc puncture. Eur Spine J. 2006;15:370–376.
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, McKeown B, Harrington D, et al. Mucormycosis osteomyelitis causing avascular necrosis of the cuboid bone: MR imaging findings. Am J Roentgenol. 1992;159:1035–1037.
   PubMed Web of Science ®Google Scholar
• Wilkins RM, Hahn DB, Blum R. Bread mold osteomyelitis in the femur. Orthopedics. 2009;32:362.
   PubMedGoogle Scholar
• Vashi N, Avedian R, Brown J, et al. Successful surgical and medical treatment of rhizopus osteomyelitis following hematopoietic cell transplantation. Orthopedics. 2012;35:e1556–e1561.
   PubMed Web of Science ®Google Scholar
• Cohen-Abbo A, Edwards KM. Multifocal osteomyelitis caused by Paecilomyces varioti in a patient with chronic granulomatous disease. Infection. 1995;23:55–57.
   PubMed Web of Science ®Google Scholar
• Adam RD, Paquin ML, Petersen EA, et al. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature. Medicine (Baltimore). 1986;65:203–217.
   PubMed Web of Science ®Google Scholar
• Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.
   PubMed Web of Science ®Google Scholar
• Sierra-Hoffman M, Paltiyevich-Gibson S, Carpenter JL, et al. Fusarium osteomyelitis: case report and review of the literature. Scand J Infect Dis. 2005;37:237–240.
   PubMed Web of Science ®Google Scholar
• Bourgeois GP, Cafardi JA, Sellheyer K, et al. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis. 2010;85:191–194.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen GS, Lan CCE. Onychomycosis caused by Fusarium solani in a woman with diabetes. Clin Exp Dermatol. 2009;34:e772–e774.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med. 2004;25:159–169.
   PubMed Web of Science ®Google Scholar
• Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008;36:296–313.
   PubMed Web of Science ®Google Scholar
• Davies F, Logan S, Johnson E, et al. Sternal wound infection by Trichosporon inkin following cardiac surgery. J Clin Microbiol. 2006;44:2657–2659.
   PubMed Web of Science ®Google Scholar
• Baraboutis I, Belesiotou E, Platsouka E, et al. Poststernotomy sternal osteomyelitis and mediastinitis by Trichosporon asahii: a rare occurrence with a grave prognosis. Mycoses. 2010;53:272–274.
   PubMed Web of Science ®Google Scholar
• Waryasz GR, Bariteau JT. Trichophyton rubrum osteomyelitis after calcaneus external fixation pin stabilization of a pilon fracture. J Foot Ankle Surg. 2014;53:480–484.
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Mori K, Nishimura Y, et al. Osteocartilaginous involvement in Blastoschizomyces capitatus (Trichosporon capitatum) infection in a bone marrow transplant recipient. Br J Haematol. 2004;124:405.
   PubMedGoogle Scholar
• Liu PY. Cryptococcal osteomyelitis: case report and review. Diagn Microbiol Infect Dis. 1998;30:33–35.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Ghandour J. Cryptococcus neoformans abscess and osteomyelitis in an immunocompetent patient with tuberculous lymphadenitis. Infection. 2007;35:377–382.
   PubMed Web of Science ®Google Scholar
• Legarth RA, Christensen M, Calum H, et al. Cryptococcal rib osteomyelitis as primary and only symptom of idiopathic CD4 penia. Med Mycol Case Rep. 2014;4:16–18.
   PubMedGoogle Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86:805–817.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360.
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16:603–616.
   PubMed Web of Science ®Google Scholar
• Sealy PI, Nguyen C, Tucci M, et al. Delivery of antifungal agents using bioactive and nonbioactive bone cements. Ann Pharmacother. 2009;43:1606–1615.
   PubMed Web of Science ®Google Scholar
• Rouse MS, Heijink A, Steckelberg JM, et al. Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro? Clin Orthop Relat Res. 2011;469:1466–1469.
   PubMed Web of Science ®Google Scholar
• Grimsrud C, Raven R, Fothergill AW, et al. The in vitro elution characteristics of antifungal-loaded PMMA bone cement and calcium sulfate bone substitute. Orthopedics. 2011;34:e378–e381.
   PubMed Web of Science ®Google Scholar
• Miller AO, Gamaletsou MN, Henry MW, et al. Successful treatment of Candida osteoarticular infections with limited duration of antifungal therapy and orthopedic surgical intervention. Infect Dis (London, England). 2015;47:144–149.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Cabellos C, Ayats J, et al. Fungal postoperative spondylodiscitis due to Scedosporium prolificans. Spine J. 2009;9:e1–e7.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1–e50.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48:503–535.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–2482.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–1122.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363–369.
   PubMed Web of Science ®Google Scholar
• Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis. 2001;33:523–530.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Huprikar S, Reboli A, et al. Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance(R) registry. Eur J Clin Microbiol Infect Dis. 2014;33:135–141.
   PubMed Web of Science ®Google Scholar
• Schilling A, Seibold M, Mansmann V, et al. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol. 2008;46:79–83.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, et al. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:651–655.
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Sabatakou H, et al. Case report. Successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole). Mycoses. 2001;44:422–425.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis. 1997;25:608–613.
   PubMed Web of Science ®Google Scholar
• Hendrickx L, Van Wijngaerden E, Samson I, et al. Candidal vertebral osteomyelitis: report of 6 patients, and a review. Clin Infect Dis. 2001;32:527–533.
   PubMed Web of Science ®Google Scholar
• Malani PN, McNeil SA, Bradley SF, et al. Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy. Clin Infect Dis. 2002;35:1316–1320.
   PubMed Web of Science ®Google Scholar
• Marra F, Robbins GM, Masri BA, et al. Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans. Can J Surg. 2001;44:383–386.
   PubMed Web of Science ®Google Scholar
• Ueng SWN, Lee C-Y, Hu C, et al. What is the success of treatment of hip and knee candidal periprosthetic joint infection? Clin Orthop Relat Res. 2013;471:3002–3009.
   PubMed Web of Science ®Google Scholar
• Dutronc H, Dauchy FA, Cazanave C, et al. Candida prosthetic infections: case series and literature review. Scand J Infect Dis. 2010;42:890–895.
   PubMed Web of Science ®Google Scholar
• Anagnostakos K, Kelm J, Schmitt E, et al. Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol. J Arthroplasty. 2012;27:293–298.
   PubMed Web of Science ®Google Scholar
• Denes E, Fiorenza F, Saint-Marcoux F, et al. Voriconazole stability in cement spacers. Med Mal Infect. 2012;42:567–568.
   PubMed Web of Science ®Google Scholar
• Miller RB, McLaren AC, Pauken C, et al. Voriconazole is delivered from antifungal-loaded bone cement. Clin Orthop Relat Res. 2013;471:195–200.
   PubMed Web of Science ®Google Scholar
• Schmidt K, McLaren A, Pauken C, et al. Voriconazole is cytotoxic at locally delivered concentrations: a pilot study. Clin Orthop Relat Res. 2013;471:3165–3170.
   PubMed Web of Science ®Google Scholar
• Kweon C, McLaren AC, Leon C, et al. Amphotericin B delivery from bone cement increases with porosity but strength decreases. Clin Orthop Relat Res. 2011;469:3002–3007.
   PubMed Web of Science ®Google Scholar
• Goss B, Lutton C, Weinrauch P, et al. Elution and mechanical properties of antifungal bone cement. J Arthroplasty. 2007;22:902–908.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, et al. Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI. Enferm Infecc Microbiol Clin. 2019;37:535–541.
   PubMed Web of Science ®Google Scholar
• Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870–1884.
   PubMed Web of Science ®Google Scholar
• Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients–recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009;88:97–110.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415.
   PubMed Web of Science ®Google Scholar
• Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis. 2005;40:1141–1147.
   PubMed Web of Science ®Google Scholar
• Stratov I, Korman TM, Johnson PDR. Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis. 2003;22:277–283.
   PubMed Web of Science ®Google Scholar
• John J, Loo A, Mazur S, et al. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15:881–895.
   PubMed Web of Science ®Google Scholar
• Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 2011;71:2405–2419.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53:1712–1714.
   PubMed Web of Science ®Google Scholar
• Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12:881–895.
   PubMed Web of Science ®Google Scholar
• Witzig RS, Greer DL, Hyslop NEJ. Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole. J Med Vet Mycol. 1996;34:133–137.
   PubMedGoogle Scholar
• Tang TJ, Janssen HL, van der Vlies CH, et al. Aspergillus osteomyelitis after liver transplantation: conservative or surgical treatment? Eur J Gastroenterol Hepatol. 2000;12:123–126.
   PubMed Web of Science ®Google Scholar
• Lodge BA, Ashley ED, Steele MP, et al. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol. 2004;42:1376–1378.
   PubMed Web of Science ®Google Scholar
• Hodiamont CJ, Dolman KM, Ten Berge IJM, et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol. 2009;47:217–220.
   PubMed Web of Science ®Google Scholar
• Kirby A, Hassan I, Burnie J. Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect. 2006;52:405–414.
   PubMed Web of Science ®Google Scholar
• Studemeister A, Stevens D. Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infect Dis. 2011;52:e1–e6.
   PubMed Web of Science ®Google Scholar
• Vinas FC, King PK, Diaz FG. Spinal Aspergillus Osteomyelitis. Clin Infect Dis [Internet]. 1999;28:1223–1229. Available from: http://www.jstor.org/stable/4481858
   PubMed Web of Science ®Google Scholar
• Sponseller PD, Malech HL, McCarthy EF, et al. Skeletal involvement in children who have chronic granulomatous disease. J Bone Joint Surg Am. 1991;73:37–51.
   PubMedGoogle Scholar
• The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The international chronic granulomatous disease cooperative study group. N Engl J Med. 1991;324:509–516.
   PubMed Web of Science ®Google Scholar
• Assari T. Chronic Granulomatous disease; fundamental stages in our understanding of CGD. Med Immunol. 2006;5:4.
   PubMedGoogle Scholar
• Errante PR, Frazao JB, Condino-Neto A. The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov. 2008;3:225–230.
   PubMedGoogle Scholar
• Roilides E, Uhlig K, Venzon D, et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 1993;61:1185–1193.
   PubMed Web of Science ®Google Scholar
• Drewniak A, Kuijpers TW. Granulocyte transfusion therapy: randomization after all? Haematologica. 2009;94:1644–1648.
   PubMed Web of Science ®Google Scholar
• Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20(Suppl 6):74–81.
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–197.
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AMS, van Diepeningen AD, Curfs-Breuker I, et al. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015;70:1068–1071.
   PubMed Web of Science ®Google Scholar
• Guarro J, Kantarcioglu AS, Horre R, et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006;44:295–327.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19:e405–e421.
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98:e127–e130.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39:310–324.
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–371.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012;54(Suppl 1):S73–S78.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Rüping MJGT. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect. 2009;15:77–81.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Mullane K, van Burik J-AH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–133.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Kwon J-C, Kim S-H, et al. Posaconazole treatment in Korea: single-center experience over 5 years. Yonsei Med J. 2013;54:1234–1240.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J Chemother. 2003;15:16–27.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359–370.
   PubMed Web of Science ®Google Scholar
• Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–1750.
   PubMed Web of Science ®Google Scholar
• Angelini A, Drago G, Ruggieri P. Post-tsunami primary Scedosporium apiospermum osteomyelitis of the knee in an immunocompetent patient. Int J Infect Dis. 2013;17:e646–e649.
   PubMed Web of Science ®Google Scholar
• Kesson AM, Bellemore MC, O’Mara TJ, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48:1257–1261.
   PubMed Web of Science ®Google Scholar
• Seidel D, Meer A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope((R)). Crit Rev Microbiol. 2019;45:1–21.
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Vehreschild MJGT, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20:580–585.
   PubMed Web of Science ®Google Scholar
• Nuovo MA, Simmonds JE, Chacho MS, et al. Fusarium solani osteomyelitis with probable nosocomial spread. Am J Clin Pathol. 1988;90:738–741.
   PubMed Web of Science ®Google Scholar
• Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805–809.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291–322.
   PubMed Web of Science ®Google Scholar
• Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am. 2005;19:831–851.
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of America. Clin Infect Dis. 2008;46:1801–1812.
   PubMed Web of Science ®Google Scholar
• Chapman SW, Bradsher RWJ, Campbell GDJ, et al. Practice guidelines for the management of patients with blastomycosis. Infectious diseases society of America. Clin Infect Dis. 2000;30:679–683.
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America. Clin Infect Dis. 2007;45:1255–1265.
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Ampel NM, Blair JE, et al. Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–e146.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–825.
   PubMed Web of Science ®Google Scholar
• Menezes VM, Soares BGO, Fontes CJF. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev. 2006;2:CD004967.
   Google Scholar
• Shikanai-Yasuda MA, Mendes RP, Colombo AL, et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop. 2017;50:715–740.
   PubMed Web of Science ®Google Scholar
• Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg. 2007;77:350–353.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Goldani LZ, Schlamm HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis. 2007;45:1462–1469.
   PubMed Web of Science ®Google Scholar
• Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734–1736.
   PubMed Web of Science ®Google Scholar
• Liu D, Liang L, Chen J. In vitro antifungal drug susceptibilities of Penicillium marneffei from China. J Infect Chemother. 2013;19:776–778.
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L, Sutton DA, et al. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 1997;41:1832–1834.
   PubMed Web of Science ®Google Scholar
• Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53:1648–1651.
   PubMed Web of Science ®Google Scholar
• Bunce PE, Yang L, Chun S, et al. Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole. Med Mycol. 2012;50:197–201.
   PubMed Web of Science ®Google Scholar
• Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother. 2012;56:4029.
   PubMed Web of Science ®Google Scholar
• Goncalves D, Ferraz C, Vaz L. Posaconazole as rescue therapy in African histoplasmosis. Braz J Infect Dis. 2013;17:102–105.
   PubMed Web of Science ®Google Scholar
• Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54:319–327.
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009–2015.
   PubMed Web of Science ®Google Scholar
• Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis. 2007;45:562–568.
   PubMed Web of Science ®Google Scholar
• Suominen MM, Tulamo RM, Puupponen LM, et al. Effects of intra-articular injections of bufexamac suspension on amphotericin B-induced aseptic arthritis in horses. Am J Vet Res. 1999;60:1467–1473.
   PubMed Web of Science ®Google Scholar
• Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on the Horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7:ofaa016.
   PubMed Web of Science ®Google Scholar